Despite evidence that topical cannabinoids may relieve symptoms, more research is needed.
AXIM Biotech announced in March the issuance of a Notice of Allowance for a U.S. patent on a method to treat atopic dermatitis with a topical containing the cannabinoids cannabidiol and cannabigerol.
As a nutraceutical, there will be no need for a doctor’s prescription. AXIM aims to market the topical in the third quarter, likely through a third-party vendor, according to the media relations team that distributed the news.
The patent is for a cream formulation that relieves itching, pain and inflammation.
“All creams formulated under this patent will contain cannabinoids and utilize AXIM’s proprietary combination of [cannabigerol] CBG and [cannabidiol] CBD,” according to a company press release.
Dermatology Times requested clinical data on the AXIM topical, but the media relations contact wrote in an email that AXIM doesn’t have clinical data that it’s prepared to share at this time.
Gary Goldenberg, M.D., assistant clinical professor of dermatology at The Icahn School of Medicine at Mount Sinai Hospital in New York City, was among the authors of one of the first clinical reviews on topical cannabinoids in dermatology in 2017.
He tells Dermatology Times that there is scientific evidence that cannabinoids have anti-inflammatory properties. But more data is needed.
“I think we need to do some rigorous scientific studies. And I think there will be some products that are better formulated than others,” Dr. Goldenberg says. “But I do think that there is some evidence at this point that topical cannabinoids may actually prove to have some efficacy for patients who suffer from eczema.”